DNA Ginkgo Bioworks Holdings Inc

  1. Stocks
  2. Healthcare
  3. NYSE: DNA

Price (delayed)

$0.955

Market cap

$2.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.46

Enterprise value

$1.33B

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline ...

Highlights
The debt is down by 46% year-on-year and by 45% since the previous quarter
DNA's gross margin is up by 37% year-on-year and by 4.1% since the previous quarter
The EPS has surged by 63% year-on-year but it has declined by 10% since the previous quarter
The net income has soared by 58% YoY but it has contracted by 4.2% from the previous quarter
The revenue has declined by 47% year-on-year and by 20% since the previous quarter
The equity is down by 37% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://ginkgobioworks.com
Peers: OMER OMGA

Key stats

What are the main financial stats of DNA
Market
Shares outstanding
2.15B
Market cap
$2.06B
Enterprise value
$1.33B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.84
Price to sales (P/S)
7.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.3
Earnings
Revenue
$251.46M
EBIT
-$892.85M
EBITDA
-$792.98M
Free cash flow
-$331.87M
Per share
EPS
-$0.46
Free cash flow per share
-$0.17
Book value per share
$0.52
Revenue per share
$0.13
TBVPS
$0.79
Balance sheet
Total assets
$1.67B
Total liabilities
$568.19M
Debt
$221.84M
Equity
$1.1B
Working capital
$837.89M
Liquidity
Debt to equity
0.2
Current ratio
6.11
Quick ratio
5.87
Net debt/EBITDA
0.91
Margins
EBITDA margin
-315.4%
Gross margin
78.5%
Net margin
-355.1%
Operating margin
-343.8%
Efficiency
Return on assets
-42.5%
Return on equity
-65.4%
Return on invested capital
-84.5%
Return on capital employed
-59.5%
Return on sales
-355.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DNA stock price

How has the Ginkgo Bioworks Holdings stock price performed over time
Intraday
11.05%
1 week
11.05%
1 month
-12.39%
1 year
-16.96%
YTD
-43.49%
QTD
-17.67%

Financial performance

How have Ginkgo Bioworks Holdings's revenue and profit performed over time
Revenue
$251.46M
Gross profit
$197.45M
Operating income
-$864.41M
Net income
-$892.87M
Gross margin
78.5%
Net margin
-355.1%
DNA's operating income has surged by 61% year-on-year and by 6% since the previous quarter
The net income has soared by 58% YoY but it has contracted by 4.2% from the previous quarter
The revenue has declined by 47% year-on-year and by 20% since the previous quarter
DNA's gross margin is up by 37% year-on-year and by 4.1% since the previous quarter

Growth

What is Ginkgo Bioworks Holdings's growth rate over time

Valuation

What is Ginkgo Bioworks Holdings stock price valuation
P/E
N/A
P/B
1.84
P/S
7.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.3
The EPS has surged by 63% year-on-year but it has declined by 10% since the previous quarter
The equity is down by 37% year-on-year and by 12% since the previous quarter
The price to book (P/B) is 29% lower than the last 4 quarters average of 2.6
The revenue has declined by 47% year-on-year and by 20% since the previous quarter
The stock's price to sales (P/S) is 30% less than its last 4 quarters average of 10.5

Efficiency

How efficient is Ginkgo Bioworks Holdings business performance
The company's return on invested capital has surged by 74% YoY but it fell by 18% QoQ
The company's return on assets has surged by 57% YoY but it fell by 15% QoQ
The ROE has soared by 51% YoY but it has contracted by 16% from the previous quarter
The return on sales has declined by 28% since the previous quarter but it rose by 20% year-on-year

Dividends

What is DNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNA.

Financial health

How did Ginkgo Bioworks Holdings financials performed over time
Ginkgo Bioworks Holdings's total assets is 193% higher than its total liabilities
Ginkgo Bioworks Holdings's total assets has decreased by 34% YoY and by 18% QoQ
DNA's total liabilities is down by 29% YoY and by 27% from the previous quarter
The debt is 80% smaller than the equity
The debt is down by 46% year-on-year and by 45% since the previous quarter
The debt to equity has contracted by 38% from the previous quarter and by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.